|Articles|August 10, 2010

EGA Talks Biosimilars

The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars.

Click here.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

The Situation We Faced: The Hard Lessons of Scaling Stem Cell Production

ByChris Spivey

October 15th 2025

Advancing Neuroscience and Rare Disease Innovation

ByMike Hollan

October 14th 2025

The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.

ByAnaïs Frappé,Mark Kohler,Daniel Shapiro

October 13th 2025

Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina

ByNicholas Jacobus

October 10th 2025

How Will US Drug Price Negotiations Impact Global Market Dynamics?

ByMike Hollan,William Soliman, PhD

October 9th 2025

EGA Talks Biosimilars

Newsletter

Related Content

The Situation We Faced: The Hard Lessons of Scaling Stem Cell Production

Advancing Neuroscience and Rare Disease Innovation

The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.

Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina

How Will US Drug Price Negotiations Impact Global Market Dynamics?

Trending on PharmExec

Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro

FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps

Navigating the Complexities of a Global Pharma Expansion